The FDA has approved an updated label for IBTROZI (taletrectinib), a treatment for ROS1-positive non-small cell lung cancer (NSCLC), reflecting a median duration of response of nearly 50 months in TKI-naïve patients from the TRUST-I study. This update confirms long-term clinical benefit and safety with no new safety concerns after extended follow-up. The approval, granted four months ahead of schedule, reinforces IBTROZI as a durable and tolerable treatment option for advanced ROS1+ NSCLC. Nuvation Bio continues to advance global regulatory efforts and ongoing clinical trials for this therapy.
The FDA approval update for IBTROZI® highlights a median duration of response of nearly 50 months in TKI-naïve advanced ROS1-positive non-small cell lung cancer patients. For readers following the health sector, here is Pluang's market snapshot as of Sep 17, 2026 18:11 WIB: out of 91 priced US health stocks, 63 rose and 25 fell. Notable movers include Sana Biotechnology Inc (SANA) at USD 3.00 with 86% sell order activity, Twist Bioscience Corp (TWST) at USD 146.86 with nearly balanced buy/sell activity, and BioNano Genomics Inc (BNGO) at USD 1.55 with 77% sell order activity.
Dimensional Fund Advisors Ltd. has publicly disclosed holding a 1.28% ownership stake in Prologis Inc, amounting to 12,123,997 shares as of October 7, 2026. This disclosure is made under Rule 8.3 of the Takeover Code, indicating significant interest ...
QAIX, a Quantum Computing & AI Alliance based in Manhattan, has opened its global membership program offering companies and tech leaders access to a global network, office spaces in major cities including New York, and resources from NVIDIA and IBM. ...
FLSmidth secured a DKK 360 million contract to supply advanced crushing and grinding equipment for a copper mine expansion in Northern Chile. The order includes the world's largest gyratory crusher, a large SAG mill, and three ball mills, with instal...
On October 8, 2026, Michelin repurchased 202,417 of its own ordinary shares at a weighted average price of €32.33 per share through over-the-counter transactions. The shares bought back are intended for cancellation, which can reduce the total number...
On October 8, 2026, Michelin executed a share buyback, purchasing 202,417 ordinary shares at a weighted average price of €32.33 per share. The shares were acquired through over-the-counter transactions involving several financial institutions and are...
